PGNY Company Profile and Key Details

Progyny, Inc. has 85.98 million shares outstanding. The public float is 79.59 million shares, elevated short interest at 11.18% of float. This equals 6.95 million shares. The short ratio is 6.22 days. Institutional investors hold 112.39% of the float. Insiders own 7.58%. TPG GP A, LLC holds 6.35 million shares, Anevski Peter has 680.25 thousand shares and Sturmer Michael E has 362.58 thousand shares. Over the past six months, insider transactions show net selling. They sold 27.90 thousand shares across 7 transactions.

Short-term trend indicators are mixed aligned (SMA20 -10.35%, SMA50 -14.44%, SMA200 -5.99%). The stock’s 14-day RSI is 30.49 (weak momentum), while the ATR of 0.99 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -25.15% below its high and over 19.71% above its low. Average 10-day trading volume of 1.29 million shares is below the 3-month average of 1.49 million, indicating normal recent market interest.

Our AI price prediction model suggests that Progyny, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.27%, with price expected at $20.17 by February 23, 2026, within a range of $19.35 to $20.92 3-Month Outlook: Projected fall of -67.84%, reaching $6.92 by May 08, 2026, with a range of $6.01 to $7.62. 1-Year Outlook: Projected loss of -24.21%, with price at $16.31 by February 09, 2027, within a range of $14.47 to $17.94.

Wall Street analysts project EPS growth of 25.91% annually over the next five years. The latest quarter delivered EPS of $0.15. The next quarter is forecast at $0.15. Next year's EPS is expected at $22.05. Analyst sentiment is neutral. Analyst rating data shows there are 6 Strong Buy ratings, 2 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $23.00. The high target offers 48.7% upside. The low target suggests 6.88% downside. The mean target is $27.14. This offers 26.12% upside. Progyny, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by -61.54%. The prior quarter beat by 9.09%. Over the last six quarters, Apple has recorded several small beats. These include 19.44% in August 06, 2024.

Progyny, Inc. (NASDAQ:PGNY) shares are flat -1.17% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Progyny, Inc. trading at a premium to the broader market with a P/E of 32.89. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $38.17, suggesting 77.37% upside. Our AI forecast model points to short-term weakness (-6.27% over two weeks), a medium-term fall (-67.84% over three months), and a longer-term loss (-24.21% over one year), with expected trading ranges indicating moderate volatility.

Progyny, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.93. This means the shares are trading above this model’s fair value.

Progyny, Inc. (NASDAQ:PGNY) closed at $21.52 USD, losing -$0.13 (-0.60%) from the previous close of $21.65. The stock is currently mid-range between its 52-week high and low $17.98 and $28.75. With a market capitalization of about $1.86 billion, Progyny, Inc. is classified as a small-cap and shows market-like volatility (beta ~0.97). Key stats such as the average daily volume over the past year has been around 1.49 million shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Progyny, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Peter Anevski, the company employs approximately 675 people and listed since October 25, 2019. Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States.

Progyny, Inc. trades at a P/E ratio of 32.89, slightly above the S&P 500 average, with a price-to-sales ratio of 1.47 and a price-to-book ratio of 3.32 trading at moderately above to book value. The P/FCF stands at 9.8, also above market averages.